Merck & Co.
AWARDS
NEWS
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
Merck’s Keytruda has become one of the best-selling drugs in the world. Last year, it generated more than $7 billion in revenue for Merck and that is only predicted to grow, particularly as the drug wins approval for new indications.
Privately-held Oncologie will conduct a Phase II study of the combination study for patients who have failed at least one line of treatment for gastric or gastroesophageal cancer.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
JOBS
IN THE PRESS